|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR-DDD-17012729 |
|
最近更新日期: Date of Last Refreshed on: |
2017-09-30 14:40:13 |
|
注册时间: Date of Registration: |
2017-09-14 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
急性缺血性脑血管病侧支循环评估与预后的队列研究 |
|
Public title: |
Cerebral Collateral Circulation evaluation and Prediction for acute cerebral ischemia in China |
|
注册题目简写: |
|
|
English Acronym: |
COLLATERAL |
|
研究课题的正式科学名称: |
急性缺血性脑血管病侧支循环评估与预后的队列研究 |
|
Scientific title: |
Cerebral Collateral Circulation evaluation and Prediction for acute cerebral ischemia in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
濮月华 |
研究负责人: |
刘丽萍 |
|
Applicant: |
Yuehua Pu |
Study leader: |
Liping Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 13146544856 |
研究负责人电话:
Study leader's |
+86 13331159535 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chinesemoonpu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lipingsister@gmal.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市东城区天坛西里6号 |
研究负责人通讯地址: |
北京市东城区天坛西里6号 |
|
Applicant address: |
6 Tiantan Lane West, Dongcheng District, Beijing, China |
Study leader's address: |
6 Tiantan Lane West, Dongcheng District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100050 |
研究负责人邮政编码: Study leader's postcode: |
100050 |
|
申请人所在单位: |
首都医科大学附属北京天坛医院 |
||
|
Applicant's institution: |
Beijing Tiantan Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属北京天坛医院 |
||
|
Affiliation of the Leader: |
Beijing Tiantan Hospital, Capital Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2016-026-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京天坛医院 |
||
|
Name of the ethic committee: |
Beijing Tiantan Hospital, Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2016-06-17 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
首都医科大学附属北京天坛医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Tiantan Hospital of Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市东城区天坛西里6号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
6 Tiantan Lane West, Dongcheng District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
石药集团恩必普药业有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
CSCP NBP Pharmaceutical cooperation |
||||||||||||||||||||||
|
研究疾病: |
急性缺血性脑血管病 |
||||||||||||||||||||||
|
Target disease: |
acute ischemic stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
1) 评估脑侧支循环及脑血流动力学因素对颅内动脉粥样硬化所致的急性缺血性脑血管病患者预后的预测价值; 2) 建立评估侧支循环的可靠方法及标准化的脑侧支影像评估体系,为后期开展侧支循环的药物干预研究奠定基础; 3) 探讨脑侧支循环形成的时限及影响因素,寻找可干预靶点; 4) 探讨脑血流储备与侧支循环的关系及其对症状性颅内动脉狭窄患者的预后价值; |
||||||||||||||||||||||
|
Objectives of Study: |
1. To assess the predictive value of the cerebral collateral circulation and hemodynamic factors for patients with acute ischemic cerebrovascular disease accompanied by intracranial atherosclerosis ; 2. To establish reliable methods for evaluating collateral circulation and standardize collateral imaging evaluation system, and to lay a foundation for the further intervention studies; 3. To investigate the time limit and influencing factors of the cerebral collateral circulation, so as to find the potential intervention targets; 4. To investigate the relationship of cerebral blood flow reserve and collateral circulation, and the predictive value of cerebral blood flow reserve on 1-year outcome for symptomatic intracranial atherosclerosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
NA |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
NA |
||||||||||||||||||||||
|
纳入标准: |
1. 发病7天内的缺血性脑血管病患者(包括脑梗死和TIA);(TIA患者的发病时间按照就诊前最后一次发作时间距离住院的日期计算) |
||||||||||||||||||||||
|
Inclusion criteria |
1. Within 7 days of onset of ischemic cerebrovascular disease (including the cerebral infarction and TIA); (The disease time of TIA is calculated from the last attack time before seeing a doctor to admission date) |
||||||||||||||||||||||
|
排除标准: |
1. 本次发病前mRS评分>2分; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The mRS score before onset >2; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2016-06-30 00:00:00至 To 2017-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2016-06-30 00:00:00 至 To 2019-12-31 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过ResMan提供原始数据查询 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
IPD will be public accessable via ResMan |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究所有患者在经过严格的入排标准筛选后入组。入组患者数据均采用统一的电子病历系统进行采集,包括患者入院基线信息、临床信息、影像信息、化验检查、治疗情况以及后续随访信息。入组患者在规定时间内完成信息采集,并提交信息,由临床数据监察员对所填写进行进行核对质控,对存在疑问的信息提出质疑并要求研究者必须修订。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All patients in the study were enrolled after rigorous screening criteria. The data of patients in the group were collected by a unified electronic medical record system(Electronic Data Capture, EDC)), including baseline information, clinical information, image information, laboratory examination, treatment and follow-up information. The patients within the specified time to complete the information collection, and submit the information to fill in to check the quality of inspectors from the clinical data, there are questions about the question and request of information must be revised. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |